Early Generic Semaglutide in Canada—Implications for US Patients and Policy

JAMA Internal Medicine 2026

View at publisher
Authors: S. Sean Tu, Aaron S. Kesselheim, Mina Tadrous, Reed F. Beall
DOI: 10.1001/jamainternmed.2026.2209
Cited by: 1
References: 7

Abstract

This Viewpoint explores the emergence of generic versions of semaglutide in Canada and the implications for US patients.

Fields of Study & Subjects

Diabetes Treatment and Management Medication Adherence and Compliance Lipoproteins and Cardiovascular Health

Publication details

Journal / source
JAMA Internal Medicine
Publisher
American Medical Association (AMA)
Volume
186
Issue
8
Pages
921–921
Publication date
8 June 2026
Language
EN